MX2009005335A - El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. - Google Patents

El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.

Info

Publication number
MX2009005335A
MX2009005335A MX2009005335A MX2009005335A MX2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A MX 2009005335 A MX2009005335 A MX 2009005335A
Authority
MX
Mexico
Prior art keywords
treatment
manufacture
pregnane
cns disorders
pharmaceutical composition
Prior art date
Application number
MX2009005335A
Other languages
English (en)
Inventor
Torbjoern Baeckstroem
Gianna Ragagnin
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Publication of MX2009005335A publication Critical patent/MX2009005335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos esferoidales que tienen resistencia creciente contra el metabolismo y solubilidad creciente en agua, junto con métodos para su producción. Estas sustancias son adecuadas para la fabricación de productos farmacéuticos para el tratamiento de trastornos del SNC inducidos por esteroides o relacionados con esteroides y para uso en métodos de prevención, alivio o tratamiento de dichos trastornos.
MX2009005335A 2006-11-21 2007-11-20 El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc. MX2009005335A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2009005335A true MX2009005335A (es) 2009-06-08

Family

ID=39429970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005335A MX2009005335A (es) 2006-11-21 2007-11-20 El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.

Country Status (16)

Country Link
US (9) US8580983B2 (es)
EP (4) EP2792681B1 (es)
JP (5) JP5386362B2 (es)
AU (1) AU2007322423C1 (es)
BR (2) BRPI0718945B8 (es)
CA (2) CA2833976C (es)
DK (3) DK2711371T3 (es)
ES (3) ES2543841T3 (es)
HU (3) HUE036410T2 (es)
IN (1) IN2014DN02014A (es)
MX (1) MX2009005335A (es)
PL (3) PL2097437T3 (es)
PT (1) PT2097437E (es)
RU (1) RU2458065C2 (es)
SI (1) SI2097437T1 (es)
WO (1) WO2008063128A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005335A (es) * 2006-11-21 2009-06-08 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
BR112012017136B1 (pt) 2010-01-14 2021-05-25 Umecrine Mood Ab composição farmacêutica compreendendo 3-beta-hidróxi5-alfa-pregnan-20-ona, colesterol e uma mistura de acilgliceróis, método para preparar dita composição farmacêutica, bem como usos da mesma para o tratamento ou prevenção de condições do sistema nervoso central e para cessar a anestesia induzida por esteroide
US20130203718A1 (en) * 2010-05-07 2013-08-08 Marie-Edith Rafestin-Oblin Progesterone receptor antagonists and uses thereof
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
RS55803B1 (sr) * 2012-11-28 2017-08-31 Inst Nat De La Santé Et De La Rech Médicale (Inserm) 3-(4'-supstituisani)-benzil-etar derivati pregnenolona
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
SI3099306T1 (sl) 2014-01-29 2019-03-29 Umecrine Cognition Ab Steroidna spojina za uporabo v zdravljenju hepatične encefalopatije
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
ME03749B (me) * 2014-11-27 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
TWI748936B (zh) * 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
FI3579843T3 (fi) 2017-02-10 2026-01-19 Relmada Therapeutics Inc 3-beetahydroksi-5-alfapregnan-20-oni touretten oireyhtymän, pakko-oireisen häiriön ja uhkapeliriippuvuuden hoitoa varten
CN111432805B (zh) 2017-11-27 2023-02-17 梅克里内科尼蒂翁公司 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂
WO2019193138A1 (en) 2018-04-05 2019-10-10 Asarina Pharma Aps Gaba-a antagonists for treating substance withdrawal disorders
US12415830B2 (en) 2019-01-08 2025-09-16 Chengdu kanghong pharmaceutical co ltd Steroid compound, and use thereof and preparation method therefor
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
US20240383941A1 (en) 2021-11-10 2024-11-21 Umecrine Ab 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor
EP4389129A1 (en) 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) * 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) * 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
DK0752860T3 (da) * 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
AP653A (en) * 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
EP1288220A3 (en) * 1995-06-06 2004-07-21 Euro-Celtique Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
CN1270718C (zh) 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
WO1999052532A1 (en) 1998-04-14 1999-10-21 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2363983A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (en) * 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
AU2005307151B2 (en) * 2004-11-18 2011-10-20 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of CNS disorders
MX2009005335A (es) 2006-11-21 2009-06-08 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
US20130203718A1 (en) 2010-05-07 2013-08-08 Marie-Edith Rafestin-Oblin Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
CA2664126A1 (en) 2008-05-29
US8580983B2 (en) 2013-11-12
JP5386362B2 (ja) 2014-01-15
JP5918170B2 (ja) 2016-05-18
US9200028B2 (en) 2015-12-01
US20160272670A1 (en) 2016-09-22
JP2013173782A (ja) 2013-09-05
RU2009107537A (ru) 2010-12-27
PT2097437E (pt) 2015-09-15
AU2007322423C1 (en) 2013-08-15
EP2711371A1 (en) 2014-03-26
PL2711371T3 (pl) 2018-06-29
CA2833976C (en) 2016-03-15
EP2097437A4 (en) 2012-12-26
US20140011792A1 (en) 2014-01-09
HUE036410T2 (hu) 2018-07-30
HUE033037T2 (hu) 2017-11-28
PL2792681T3 (pl) 2017-06-30
BR122013033954B1 (pt) 2021-01-12
EP2097437A1 (en) 2009-09-09
AU2007322423A1 (en) 2008-05-29
BR122013033954B8 (pt) 2021-05-25
US20150315231A1 (en) 2015-11-05
US20140011793A1 (en) 2014-01-09
CA2664126C (en) 2014-04-29
RU2458065C2 (ru) 2012-08-10
US20130102579A1 (en) 2013-04-25
EP2792681A1 (en) 2014-10-22
ES2662500T3 (es) 2018-04-06
SI2097437T1 (sl) 2015-10-30
EP2711371B1 (en) 2018-01-10
BRPI0718945B1 (pt) 2020-10-13
JP2015147774A (ja) 2015-08-20
CA2833976A1 (en) 2008-05-29
AU2007322423B2 (en) 2013-01-10
BRPI0718945B8 (pt) 2021-05-25
JP2010510210A (ja) 2010-04-02
ES2607852T3 (es) 2017-04-04
BRPI0718945A2 (pt) 2013-12-24
DK2097437T3 (en) 2015-06-29
ES2543841T3 (es) 2015-08-24
EP2792681B1 (en) 2016-10-19
JP2013177411A (ja) 2013-09-09
US20080119416A1 (en) 2008-05-22
JP2013173781A (ja) 2013-09-05
US20130281421A1 (en) 2013-10-24
DK2792681T3 (en) 2017-01-23
DK2711371T3 (en) 2018-04-16
EP2097437B1 (en) 2015-05-27
JP5657052B2 (ja) 2015-01-21
BRPI0718945A8 (pt) 2017-09-19
US20140011779A1 (en) 2014-01-09
EP2711372A1 (en) 2014-03-26
PL2097437T3 (pl) 2015-12-31
HUE026961T2 (en) 2016-07-28
WO2008063128A1 (en) 2008-05-29
US20130102578A1 (en) 2013-04-25
US8853190B2 (en) 2014-10-07
IN2014DN02014A (es) 2015-07-10

Similar Documents

Publication Publication Date Title
BRPI0718945B8 (pt) novos esteróides apresentando solubilidade em água e resistência contra metabolismo aumentadas, e métodos para sua produção
WO2008021368A3 (en) Compositions and methods for neuroprotection
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
EP2044108A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
IL184694A0 (en) New polymorphous forms of rifazimin, processes for their production and use thereof in the medicinal
PT1919450E (pt) Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2006131392A8 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
MX2009008787A (es) Moduladores 2-aminopirimidina del receptor de histamina h4.
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
WO2011022838A8 (en) Polyhydroxylated bile acids for treatment of biliary disorders
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
EP1857112A4 (en) AGAINST CANCER FOR ORAL USE WITH LIPOSOME-CONTAINING PHYTOSTEROLS AND PREVENTION OR TREATMENT OF CANCER WITH LIPOSOM
IL204194A0 (en) Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use
EP2012807A4 (en) PHARMACEUTICAL COMPOSITION FROM AN ENTEROSORBEN AND PREBIOTIKA, DOSAGE FORMS AND METHOD FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISEASES
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
PH12014501074A1 (en) Methods of using a thiazole derivative
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2007089733A3 (en) Regimens for treatment of conditions related to estrogen deficiency
WO2007108004A8 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
IL204957A (en) Derivatives of 3 - (aminoalkoxyimino) - androstane and androsten

Legal Events

Date Code Title Description
FG Grant or registration